Omnicell (OMCL) Tops Q1 EPS by 13c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Omnicell Reports First Quarter 2020 Results
May 7, 2020 4:01 PM EDT
GAAP and non-GAAP revenues of $229.7 million, up 13.4% year-over-year
GAAP net income per diluted share of $0.26, up 225.0% year-over-year
Non-GAAP net income per diluted share of $0.66, up 8.2% year-over-year
Omnicells Response to Coronavirus (COVID-19)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its first quarter ended March 31, 2020.
GAAP Results
GAAP revenues for the first quarter of 2020 were $229.7 million, up $27.2 million, or... More
